SCHEMBL2929271

SCHEMBL2929271

O=C(c1ccc(Nc2cncc(-c3cc4cc(F)ccc4[nH]3)n2)c(O)c1)N1CCNCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.43
MKNK2 Q9HBH9 5/20 0.38
MKNK1 Q9BUB5 3/20 0.38
RIPK1 Q13546 1/20 0.37
TDO2 P48775 1/20 0.37
PIM1 P11309 2/20 0.37
EGFR P00533 1/20 0.37
ERBB2 P04626 1/20 0.37
BRAF P15056 1/20 0.37
PIM3 Q86V86 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
MGLL Q99685 1/20 0.37
PTK6 Q13882 2/20 0.37
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
TLR9 Q9NR96 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
CDK6 Q00534 1/20 0.36
NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930393 0.91 CDK2 (0.44) KDRMKNK2MKNK1RIPK1TDO2
Hydrochloric Acid SCHEMBL2936353 0.88 MKNK1 (0.49) KDRMKNK2MKNK1PIM1EGFR
Trifluoroacetic Acid SCHEMBL2930403 0.87 CDK2 (0.41) KDRMKNK2MKNK1MGLLPTK6
SCHEMBL2931716 0.81 MKNK1 (0.42) MKNK2MKNK1LRRK2
SCHEMBL2927754 0.81 MKNK1 (0.42) MKNK2MKNK1LRRK2
SCHEMBL2926056 0.81 DYRK2 (0.43) KDRMKNK2MKNK1HRH4NTRK1
SCHEMBL14269675 0.81 TTK (0.43) MKNK2MKNK1BRAFLRRK2
SCHEMBL2930971 0.81 DYRK1A (0.47) KDRMKNK2MKNK1EGFRHRH4
SCHEMBL2927739 0.80 KDR (0.51) KDRRIPK1PTK6HRH4HRH3
SCHEMBL2933717 0.79 LRRK2 (0.51) MKNK2MKNK1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP claimed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP claimed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US claimed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO claimed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 KDR 3834/4885MKNK2 39/4885MKNK1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.